152 related articles for article (PubMed ID: 31535305)
21. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials.
DeFronzo RA; Buse JB; Kim T; Burns C; Skare S; Baron A; Fineman M
Diabetologia; 2016 Aug; 59(8):1645-54. PubMed ID: 27216492
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.
Charokopou M; McEwan P; Lister S; Callan L; Bergenheim K; Tolley K; Postema R; Townsend R; Roudaut M
BMC Health Serv Res; 2015 Nov; 15():496. PubMed ID: 26541516
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
[TBL] [Abstract][Full Text] [Related]
24. Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States.
Nalysnyk L; Sugarman R; Cele C; Uyei J; Ward A
J Manag Care Spec Pharm; 2018 Oct; 24(10):1002-1008. PubMed ID: 30247105
[TBL] [Abstract][Full Text] [Related]
25. Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
Palmer AJ; Roze S; Lammert M; Valentine WJ; Minshall ME; Nicklasson L; Gall MA; Spinas GA
Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S41-51. PubMed ID: 15324515
[TBL] [Abstract][Full Text] [Related]
26. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
[No Abstract] [Full Text] [Related]
27. The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.
Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Kristensen MM; Ejskjaer N
Diabetes Ther; 2022 Mar; 13(3):489-503. PubMed ID: 35187628
[TBL] [Abstract][Full Text] [Related]
28. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
[TBL] [Abstract][Full Text] [Related]
29. A cost-effectiveness analysis of intrauterine spacers used to prevent the formation of intrauterine adhesions following endometrial cavity surgery.
Schmerold L; Martin C; Mehta A; Sobti D; Jaiswal AK; Kumar J; Feldberg I; Munro MG; Lee WC
J Med Econ; 2024; 27(1):170-183. PubMed ID: 38131367
[TBL] [Abstract][Full Text] [Related]
30. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health system.
Nita ME; Eliaschewitz FG; Ribeiro E; Asano E; Barbosa E; Takemoto M; Donato B; Rached R; Rahal E
Rev Assoc Med Bras (1992); 2012; 58(3):294-301. PubMed ID: 22735220
[TBL] [Abstract][Full Text] [Related]
32. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.
Salas M; Ward A; Caro J
Clin Ther; 2002 Oct; 24(10):1690-705. PubMed ID: 12462297
[TBL] [Abstract][Full Text] [Related]
33. Budget impact of continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes who experience severe recurrent hypoglycemic episodes in Spain.
Giménez M; Elías I; Álvarez M; Quirós C; Conget I
Endocrinol Diabetes Nutr; 2017; 64(7):377-383. PubMed ID: 28745609
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic comparison of a new sustained-release formulation of glimepiride/metformin 1/500 mg combination tablet and a sustained-release formulation of glimepiride/metformin 2/500 mg combination tablet in healthy Korean male volunteers: a randomized, 2-sequence, 2-period, 2-treatment crossover study.
Shin KH; Kim SE; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
Clin Ther; 2011 Nov; 33(11):1809-18. PubMed ID: 22036245
[TBL] [Abstract][Full Text] [Related]
35. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
[TBL] [Abstract][Full Text] [Related]
36. Metformin treatment and gastrointestinal symptoms in youth: Findings from a large tertiary care referral center.
Meyers AG; Hudson J; Cravalho CKL; Matta ST; Villalobos-Perez A; Cogen F; Chung ST
Pediatr Diabetes; 2021 Mar; 22(2):182-191. PubMed ID: 33179823
[TBL] [Abstract][Full Text] [Related]
37. Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: Analysis of results from the CONSENT trial.
Ji L; Liu J; Yang J; Li Y; Liang L; Zhu D; Li Q; Ma T; Xu H; Yang Y; Zeng J; Feng B; Qu S; Li Y; Ma L; Lin S; Wang J; Li W; Song W; Li X; Luo Y; Xi S; Lin M; Liu Y; Liang Z
Diabetes Obes Metab; 2018 Apr; 20(4):1006-1013. PubMed ID: 29227571
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes.
Hwang YC; Kang M; Ahn CW; Park JS; Baik SH; Chung DJ; Jang HC; Kim KA; Lee IK; Min KW; Nam M; Park TS; Son SM; Sung YA; Woo JT; Park KS; Lee MK
Int J Clin Pract; 2013 Mar; 67(3):236-43. PubMed ID: 23336668
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
Petrie JR; Chaturvedi N; Ford I; Brouwers MCGJ; Greenlaw N; Tillin T; Hramiak I; Hughes AD; Jenkins AJ; Klein BEK; Klein R; Ooi TC; Rossing P; Stehouwer CDA; Sattar N; Colhoun HM;
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):597-609. PubMed ID: 28615149
[TBL] [Abstract][Full Text] [Related]
40. A budget impact analysis of substituting sitagliptin with liraglutide in type 2 diabetes from a private health insurance perspective in Egypt.
Elsisi GH; Afify A; Abgad A; Zakaria I; Nasif N; Ibrahim HN; Raafat N; Carapinha JL
Cost Eff Resour Alloc; 2022 Jan; 20(1):1. PubMed ID: 35033094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
